ReviewTherapeutic advances in medical oncology2024

Endocrine therapy plus HER2-targeted therapy, another favorable option for HR+/HER2+ advanced breast cancer patients.

Yuehua Liang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.